Contact

All Stories

  1. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

    Article • Advances in Therapy, January 2020, Springer Science + Business Media

    Dr Alessandro Russo

  2. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

    Article • Cancers, January 2020, MDPI AG

    Dr Alessandro Russo

  3. RET fusions in solid tumors

    Article • Cancer Treatment Reviews, December 2019, Elsevier

    Dr Alessandro Russo

  4. 55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

    Article • Annals of Oncology, December 2019, Oxford University Press (OUP)

    Dr Alessandro Russo

  5. Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

    Article • Translational Cancer Research, December 2019, AME Publishing Company

    Dr Alessandro Russo

  6. Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma

    Article • Cancers, November 2019, MDPI AG

    Dr Alessandro Russo

  7. O.01 Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are ESCAT and OncoKB Scales Reliable?

    Article • Journal of Thoracic Oncology, November 2019, Elsevier

    Dr Alessandro Russo

  8. Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC

    Article • JCO Precision Oncology, November 2019, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  9. Liquid biopsy tracking of lung tumor evolutions over time

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Alessandro Russo, Professor VINCENZO ADAMO, francesco pepe

  10. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

    Article • Critical Reviews in Oncology/Hematology, October 2019, Elsevier

    Dr Alessandro Russo

  11. 1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?

    Article • Annals of Oncology, October 2019, Oxford University Press (OUP)

    Dr Alessandro Russo

  12. P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Dr Alessandro Russo

  13. Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study

    Article • Cancers, July 2019, MDPI AG

    Dr Alessandro Russo

  14. How I treat ALK-positive non-small cell lung cancer

    Article • ESMO Open, July 2019, BMJ

    Dr Alessandro Russo

  15. Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  16. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

    Article • International Journal of Molecular Sciences, March 2019, MDPI AG

    Dr Alessandro Russo

  17. Immunotherapy use in patients with hiv and non-small-cell lung cancer: Current data

    Article • Journal of Immunotherapy and Precision Oncology, January 2019, Medknow

    Dr Alessandro Russo

  18. The changing scenario of 1 st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

    Article • Critical Reviews in Oncology/Hematology, October 2018, Elsevier

    Dr Alessandro Russo

  19. P1.04-28 Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study

    Article • Journal of Thoracic Oncology, October 2018, Elsevier

    Dr Alessandro Russo

  20. Acquired resistance in oncogene-addicted non-small-cell lung cancer

    Article • Future Oncology, June 2018, Future Medicine

    Dr Alessandro Russo

  21. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

    Article • Journal of Cellular Physiology, April 2018, Wiley

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  22. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

    Article • BMC Cancer, January 2018, Springer Science + Business Media

    Dr Alessandro Russo

  23. E22Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

    Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

    Dr Alessandro Russo

  24. N2Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung

    Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

    Dr Alessandro Russo

  25. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

    Article • Critical Reviews in Oncology/Hematology, September 2017, Elsevier

    Dr Alessandro Russo

  26. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer

    Article • Expert Opinion on Pharmacotherapy, May 2017, Taylor & Francis

    Dr Alessandro Russo, Professor VINCENZO ADAMO

  27. Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Dr Alessandro Russo

  28. P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Dr Alessandro Russo

  29. Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

    Article • Cancer Biology & Therapy, August 2016, Taylor & Francis

    Dr Alessandro Russo

  30. Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

    Article • OncoTargets and Therapy, July 2016, Dove Medical Press

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  31. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

    Article • Oncotarget, June 2016, Impact Journals, LLC

    MICHELE DE TURSI, Dr Alessandro Russo

  32. Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes.

    Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  33. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

    Article • Expert Review of Anticancer Therapy, May 2016, Taylor & Francis

    Dr Alessandro Russo

  34. H44Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung

    Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  35. H47The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis

    Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  36. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

    Article • Oncotarget, June 2015, Impact Journals, LLC

    Dr Alessandro Russo

  37. 147P * DIFFERENT METASTATIC PATTERN ACCORDING TO THE EGFR MUTATIONAL STATUS IN A COHORT OF LUNG ADENOCARCINOMAS (ADCs): A SINGLE-INSTITUTION REPORT

    Article • Annals of Oncology, April 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  38. 159P * IMPACT OF MAINTENANCE PEMETREXED IN THE MANAGEMENT OF NON-PROGRESSING MALIGNANT MESOTHELIOMAS AFTER STANDARD FIST-LINE CHEMOTHERAPY: A SINGLE INSTITUTION EXPERIENCE

    Article • Annals of Oncology, April 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  39. Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

    Article • OncoTargets and Therapy, February 2015, Taylor & Francis

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  40. NSCLC and HER2: Between Lights and Shadows

    Article • Journal of Thoracic Oncology, December 2014, Elsevier

    Dr Alessandro Russo

  41. Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EGFR-mutated and wild-type (WT) non-small cell lung cancer (NSCLC): A survival analysis.

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  42. 47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?

    Article • Lung Cancer, May 2013, Elsevier

    Dr Alessandro Russo